ArticleJACC. Case reports2026
Reversible Dasatinib-Associated Pulmonary Hypertension Managed With Dual Therapy and Hemodynamic-Guided Withdrawal.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDasatinib is a recognized cause of drug-induced pulmonary arterial hypertension (PAH), which may occasionally present with severe hemodynamic compromise. Evidence regarding optimal management and safe withdrawal of targeted therapy after recovery remains limited. CASE SUMMARY: A 41-year-old woman with chronic myeloid leukemia treated with dasatinib presented with rapidly progressive dyspnea and right heart failure, requiring intensive care admission due to cardiac tamponade. Right heart catheterization confirmed high-risk precapillary PAH (mean pulmonary artery pressure: 40 mm Hg; pulmonary vascular resistance: 8 Wood units). Dasatinib was permanently discontinued, and initial dual oral PAH therapy with macitentan and tadalafil was started, leading to rapid clinical, functional, and echocardiographic improvement. Hemodynamic reassessment demonstrated complete normalization, allowing sequential withdrawal of pulmonary vasodilator therapy under close follow-up. The patient remained asymptomatic with a sustained low-risk profile after complete treatment discontinuation. DISCUSSION: This case highlights the potential reversibility of dasatinib-associated PAH and the role of invasive reassessment to guide safe therapy de-escalation. TAKE-HOME MESSAGE: Dasatinib-associated PAH can be fully reversible, and hemodynamic-guided withdrawal of therapy may be feasible in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.